Cannabidiol (CBD) in Rheumatic Diseases (Musculoskeletal Pain)

Curr Rheumatol Rep. 2022 Jul;24(7):238-246. doi: 10.1007/s11926-022-01077-3. Epub 2022 May 3.


Purpose of review: This review will address the many uncertainties surrounding the medical use of cannabidiol (CBD). We will begin with an overview of the legal and commercial environment, examine recent preclinical and clinical evidence on CBD, explore questions concerning CBD raised by healthcare professionals and patients, investigate dosing regimens and methods of administration, and address current challenges in the accumulation of sound evidence.

Recent findings: CBD has potential for relief of symptoms of pain, sleep, and mood disturbance in rheumatology patients, but sound clinical evidence is lacking. CBD is safe when accessed from a regulated source, whereas wellness products are less reliable regarding content and contaminants. Dosing for symptom relief has not yet been established. As many rheumatology patients are trying CBD as a self-management strategy, the healthcare community must urgently accrue sound evidence for effect.

Keywords: Cannabidiol rheumatic disease; Musculoskeletal; Pain.

Publication types

  • Review

MeSH terms

  • Cannabidiol* / therapeutic use
  • Humans
  • Musculoskeletal Pain* / drug therapy
  • Musculoskeletal Pain* / etiology
  • Rheumatic Diseases* / complications
  • Rheumatic Diseases* / drug therapy


  • Cannabidiol